Akebia Therapeutics wins US patent for Vafseo with term through 2043
AKBA•Akebia Therapeutics received a US patent for Vafseo (vadadustat) that runs through January 18, 2043. The patent covers methods for managing drug-drug interactions during treatment and is eligible for Orange Book listing.
1. Patent details
The patent covers methods for managing drug-drug interactions during vadadustat treatment and is eligible for listing in the Orange Book. Fourteen other vadadustat patents are listed there, with expiration dates between 2027 and 2036.




